Amgen’s Dividend Has Grown 800% Since 2011. Here’s What It Pays Today
Amgen has raised its payout every year since 2011, yet the pace of those raises is cooling just as patent cliffs and drug price controls close in. One number shows whether the next raise, due soon, will hold up.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Amgen (NASDAQ:AMGN | AMGN Price Prediction) paid $0.28 per share per quarter in 2011, the year it initiated its dividend. Today it pays $2.52, up from $2.38 last year. The next payment goes ex-dividend November 20, 2026, and pays December 11, 2026. For retirees, quarterly dividend per share is the single number that best shows how this biotech really runs.
Quarterly Dividend Per Share: A 9x Climb in 15 Years
The payout has grown 9x since 2011, a compound pace of roughly 15.8% a year. It rose every single year: $1 in 2016, $1.60 in 2020, $2.13 in 2023, and now $2.52.
Why It Reveals More Than Earnings
EPS swings with acquisition amortization and biosimilar launches. A dividend raise is a forward commitment that management makes only when it trusts cash flow to survive the next patent cliff. Two drivers funded it. Operating cash flow rose from $5.119 billion in 2011 to $9.958 billion in 2025, while the share count fell from 912 million to 546 million, about 40% fewer shares to pay.
Coverage Looks Solid Right Now
The annualized $10.08 equals roughly 43% to 44% of 2026 non-GAAP EPS guidance of $22.90 to $23.70. In 2025, free cash flow covered dividends about 1.6 times. Third-quarter free cash flow of $3.65 billion covered the $1.363 billion payout about 2.7 times. Total debt fell to $54.0 billion from $57.3 billion in Q2, with $13.19 billion in cash.
The CFO framed the priority plainly: “You should expect continuity here as we balance investment in the best innovation and future growth with returning capital to shareholders.”
What Could Speed Up or Stall the Next Raise
The pace has cooled. The 2012 raise was about 28.6%; the 2025 raise was 5.8%, and the 2026 raise was 6%. Last year’s increase was announced on December 9, 2025, so the next signal is coming soon.
- Bullish: A raise at or above 6%, backed by growers like Repatha (+37%) and UPLIZNA (+191%) and continued debt paydown.
- Bearish: A smaller raise as Prolia (-45%) and XGEVA (-47%) decline, Enbrel’s net price falls 14% under IRA price setting, and R&D rises 11% to fund MariTide. Q3 free cash flow already fell 13.98% year over year on working capital.
Shares sit at $460.42, up 43.54% year to date, which reduces the yield to about 2.16% for new buyers.
Verdict: Mid-Single-Digit Raises Look Durable
With a payout under half of earnings, free cash flow covering it more than twice last quarter, and debt declining, Amgen’s dividend per share should keep compounding at a mid-single-digit pace, making it a more reliable read on the business than any quarterly earnings beat.
Contact [email protected] for any questions or corrections.
Chris Lange is a financial and geopolitical writer with more than a decade of experience covering a myriad of topics. He has published thousands of articles for 24/7 Wall St., with past coverage focused heavily on stocks, IPOs, healthcare, defense, global affairs, and technology.
His work has been quoted, or referenced by a number of outlets including Business Insider, USA Today, Yahoo Finance, MSN, The Motley Fool, and many other publications. A graduate of Southwestern University, he studied business with a focus on investments and has previous experience in banking and startups.
When not reading or writing the news, he is following his passion for Lacrosse, playing chess, or building solar projects with his dad.
